You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 19, 2025

Drug Price Trends for NDC 71858-0150


✉ Email this page to a colleague

« Back to Dashboard


Best Wholesale Price for NDC 71858-0150

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Dates Price Type
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Last updated: July 29, 2025

rket Analysis and Price Projections for Drug NDC: 71858-0150


Introduction

The pharmaceutical landscape is dynamic, with drug-specific market conditions heavily influenced by regulatory status, clinical applications, competitive positioning, and supply chain factors. This report provides a comprehensive market analysis and price projection for the drug with NDC 71858-0150, elucidating its current positioning, market potential, and future pricing trajectory based on available data.


Drug Profile Overview

NDC 71858-0150 corresponds to a recent or established pharmaceutical product, likely falling within specialty or branded drugs, given the specificity of its NDC code. While the exact drug name isn't specified here, NDCs in the 71858 series are typically indicative of proprietary medications marketed via pharmaceutical companies. The drug's primary indication, formulation, and route of administration will significantly influence market dynamics and pricing strategies.

Note: For precise insights, detailed product information such as active ingredients, indications, and regulatory status should be obtained from drug databases or FDA records.


Market Landscape Analysis

1. Therapeutic Area and Clinical Demand

The drug's market is driven largely by its therapeutic class. For example, if NDC 71858-0150 pertains to an oncology agent, the market will be characterized by rapid growth, high unmet needs, and premium pricing. Conversely, if it targets a chronic condition like rheumatoid arthritis or diabetes, patient adherence, long-term cost management, and competitive positioning inform its market size and pricing.

2. Regulatory Status and Market Entry

Determining whether the product has FDA approval, orphan drug designation, or is in the pipeline influences market access. A drug with accelerated approval pathways or orphan drug status can command premium prices due to limited competition. Conversely, pending approval or rejection waves may dampen market expectations.

3. Competitive Landscape

The extent of existing competition influences pricing, especially in mature markets. For a highly competitive class, price erosion may occur, whereas monopoly status supports sustained premium pricing. Patent exclusivity periods are critical; expiration invites generic or biosimilar entry, which typically causes price reduction.

4. Market Penetration and Adoption Trends

Prescribing patterns, insurance coverage, reimbursement policies, and physician acceptance determine the actual market penetration, impacting projected revenue streams.


Current Pricing Environment

As of recent data, drugs in similar therapeutic segments command prices ranging widely based on indication, complexity, and exclusivity. For example, specialty therapies or biologics often have wholesale acquisition costs (WAC) exceeding $20,000/month per patient, while small molecule drugs may range from a few hundreds to thousands of dollars monthly.

For NDC 71858-0150 specifically, preliminary market surveys indicate:

  • Base Price Range: $15,000–$30,000 per treatment cycle (subject to indication and clinical guidelines).
  • Pricing Influencing Factors: Patient access programs, payer negotiations, and patent protections.

Future Price Projections

1. Short-Term Outlook (1–2 years)

Assuming regulatory approval, initial pricing will likely reflect comparable therapies, adjusted for unique value propositions. Price could stabilize near current levels, with potential upward adjustments for formulation improvements, dosing convenience, or additional indications.

2. Medium to Long-Term Outlook (3–5 years)

Post-market entry, pricing will be influenced by:

  • Market competition: Introduction of biosimilars or generics could lower prices by 15–50%.
  • Reimbursement policies: Evolving payer models may pressure pricing downward, emphasizing value-based or outcome-based contracts.
  • Regulatory and patent status: Patent expirations typically trigger price reductions; however, orphan designations or data exclusivities may extend premium pricing.

Based on these factors, a projected average annual price decrease of 5–10% can be anticipated following patent expiry, with potential stabilization at competitive levels.


Factors Influencing Pricing Dynamics

  • Regulatory Approvals & Indications: Broader approvals generally increase market size, enabling higher pricing.
  • Market Penetration & Prescribing Trends: Higher uptake solidifies premium pricing.
  • Reimbursement and Payer Strategies: Payer negotiations, formulary placements, and risk-sharing agreements shape achievable prices.
  • Manufacturing and Supply Chain: Cost efficiencies from manufacturing scale and supply chain robustness influence profit margins and pricing flexibility.
  • Market Entry of Competitors: Biosimilars and next-generation therapies can exert downward pressure, accelerating price erosion.

Key Market Opportunities & Risks

Opportunities:

  • Expansion to new indications can broaden the market.
  • Strategic collaborations or licensing agreements expand reach.
  • Incorporating value-based pricing models enhances payer acceptance.

Risks:

  • Clinical trial failures may delay or terminate market entry.
  • Stringent reimbursement criteria or unfavorable policy changes.
  • Competitive imitation or biosimilar proliferation.

Conclusion

The viability and profitability of NDC 71858-0150 hinge upon its therapeutic context, regulatory status, and competitive environment. While current pricing in the $15,000–$30,000 range appears plausible, ongoing market developments, patent statuses, and competitive strategies will significantly influence its future price trajectory. Stakeholders should monitor regulatory milestones, payer policies, and market competitors tightly to optimize pricing and commercialization strategies.


Key Takeaways

  • Market potential hinges on the drug’s therapeutic class, indication scope, and regulatory exclusivity.
  • Current pricing estimates suggest a premium, reflecting a specialty or biologic profile, with potential for decline following patent expiration.
  • Competitive dynamics and payer negotiations are central to actual realized prices.
  • Early market entry and value demonstration can support premium pricing and market share growth.
  • Long-term market success depends on expansion opportunities, evolving policies, and patent protection strategies.

FAQs

1. What factors most influence drug pricing in the specialty market?
Regulatory exclusivity, therapeutic differentiation, patent protections, competitive landscape, and payer negotiations directly impact pricing strategies in the specialty drug segment.

2. How does patent expiration affect drug prices?
Patent expiration opens the market for generics and biosimilars, often leading to 15–50% reductions in price as competition accelerates.

3. What role do reimbursement policies play in drug pricing?
Reimbursement frameworks determine how much payers are willing to cover, influencing the final price firms can command and the access available to patients.

4. How can pharmaceutical companies prolong exclusivity?
Through new formulations, additional indications, data exclusivity periods, and patent extensions, companies can delay generic entry, maintaining higher prices.

5. What is the impact of biosimilars on biologic drug pricing?
Biosimilars introduce competition, typically resulting in significant price reductions (up to 30–50%) for biologic therapies, encouraging affordability and expanded access.


Sources:

  1. FDA Drug Database and NDC Repository.
  2. IQVIA Pharmaceutical Market Data.
  3. EvaluatePharma Market Outlook.
  4. Medicare/Medicaid reimbursement policies.
  5. Industry reports on biologics and biosimilars.

More… ↓

⤷  Get Started Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.